13 results about "Endothelial cell growth" patented technology

The present invention provides a composite vascular stent coating for regulating the growth activity of endothelial cells and a preparation method thereof; the composite vascular stent coating of the present invention uses silk nanofiber membranes as the inner and outer layers of the composite vascular stent coating, and adopts weaving technology to weave a seamless polyester tubular fabric as the core layer on the basis of the inner layer of the composite vascular stent coating; the composite vascular stent coating has a microstructure and matrix-like components that imitate the basement membrane of natural blood vessels, which is beneficial to the mechanical engagement between the outer surface of the coating and the inner side of the diseased blood vessel, stabilizes blood flow, avoids turbulence formation, and more significantly improves the adhesion, spreading, growth and proliferation ability of endothelial cells on its inner surface, quickly forms a new endothelial layer, inhibits the occurrence of thrombosis and inflammation, maintains long-term patency of the lumen, and has good application value.

The invention provides a functional beverage and an application thereof in anti-hypoxia. The functional beverage disclosed by the invention is obtained by compounding a lonicera caerulea extracting solution, an acanthopanax extracting solution and a schisandra chinensis extracting solution according to a specific ratio. The functional beverage can prolong the survival time of an organism in a closed hypoxia environment, relieve lung edema or hyperemia symptoms caused by hypoxia, relieve lung pathological changes caused by hypoxia, effectively reduce the levels of protein kinase B alpha, vascular endothelial cell growth factors and hypoxia-inducible factor-1 alpha in lungs, and improve the immunity of the lungs. Therefore, oxidative stress injury can be inhibited, the anti-hypoxia capability of an organism is improved, and a good anti-hypoxia effect is achieved. In addition, the functional beverage also has good biological safety, easily acceptable flavor and stable state, and is suitable for industrial popularization.

The invention discloses a gene modified fibroblast as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. Researches find that fibroblasts modified by the TIMP1 gene can stably secrete TIMP1 protein, the TIMP1 can promote the fibroblasts to secrete COL1A1 and Fibronectin, and the COL1A1 and the Fibronectin cooperate with each other to play a role in inhibiting growth of vascular endothelial cells, so that ingrowth of blood vessels in the intervertebral disc degeneration process is inhibited. And pathological angiogenesis in the degenerated intervertebral disc can be inhibited in a long-acting and targeted manner, so that the degeneration of the intervertebral disc is delayed.

A stent or other prosthesis may be formed by coating a single continuous wire scaffold with a polymer coating. The polymer coating may consist of layers of electrospun polytetrafluoroethylene (PTFE). Electrospun PTFE of certain porosities may permit endothelial cell growth within the prosthesis.

The invention provides a cell population and a method for obtaining the same. A cell population according to the present invention is obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a culture medium containing serum and four or less factors selected from the group consisting of stem cell factors, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin, and vascular endothelial cell growth factors.

Described herein are angiogenic stimulating compositions comprising ML141 or a derivative thereof and methods of use of said angiogenic stimulating compositions for the treatment or prevention of a disease or injury in a subject, preferably a human subject of at least 50 years of age.

The invention discloses application of L-(+)-ergothioneine in preparation of a medicine for improving vascular endothelial dysfunction of preeclampsia, and belongs to the technical field of biology. The invention discloses an application of L-(+)-ergothioneine in preparation of a medicine for improving preeclampsia vascular endothelial dysfunction. The preeclampsia vascular endothelial dysfunction is improved by adjusting an Nrf2-PPARgamma-sFlt-1 axis. After LPS modeling, the transfer amount of Nfr2 protein in a cell nucleus of a trophoblast cell is remarkably increased, and LET inhibits the transfer amount of the Nfr2 protein in the cell nucleus. LET can activate PPAR gamma so as to achieve the effect of improving the phenotype of trophoblast cell PE. After the LET treats the trophoblast cells, generated metabolites can promote growth and migration of endothelial cells.

The present invention discloses an AML organoid model and a construction method thereof, relating to the field of microfluidic chip technology. The present invention includes an AML organoid model, which is formed by 3D bioprinting and is constructed from top to bottom with a nutrient circulation mechanism, a tumor cell growth mechanism, a cell external stimulation mechanism, and an endothelial cell growth mechanism; a first flow channel is constructed in the nutrient circulation mechanism, and a first test electrode is installed in the first flow channel; a second flow channel is constructed in the tumor cell growth mechanism, and the second flow channel is filled with channel ink and a second test electrode is installed in the second flow channel; a cavity and an air supply channel are interconnected in the cell external stimulation mechanism, and the air supply channel is connected to the cavity; a third flow channel is constructed in the endothelial cell growth mechanism, and the inner wall of the third flow channel is filled with an outer layer of ink; so as to achieve the purpose of constructing a high-throughput drug sensitivity detection platform based on AML organoids by using microfluidics and 3D bioprinting technology for highly heterogeneous blood tumors such as AML.

The invention relates to the technical field of novel functional and structural materials, and discloses a preparation method of a piezoelectric response antibacterial / endothelial cell growth promoting coating material, the coating material takes a titanium alloy as a matrix, an alkali heat treatment technology is utilized to form a microstructure with a large number of OH <-> in pores on the surface of the titanium alloy, and a cation exchange method is utilized to prepare the piezoelectric response antibacterial / endothelial cell growth promoting coating material. Zinc ions are fixed to the surface of the titanium alloy, then a zinc-based metal organic framework is generated on the surface of the titanium alloy through an in-situ synthesis method, and finally the HZnO nanometer material which is stably combined and is of a hollow structure is obtained on the surface of the titanium alloy through a high-temperature calcination method. The HZnO nano material has piezoelectric characteristics, can generate micro-current and ROS, has the effects of promoting growth of endothelial cells and resisting bacteria, and further shows excellent anticoagulation and antibacterial effects. In addition, the composite coating has slow physiological degradability, and degradation products are non-toxic. The method is simple in preparation process and has potential application prospects in the field of novel functional and structural materials.

The invention belongs to the field of biological medicines, and relates to a clostridium butyricum genetically engineered bacterium BHC008-1 for secreting and expressing a human vascular endothelial cell growth inhibition factor and application of the clostridium butyricum genetically engineered bacterium BHC008-1. The invention firstly provides a clostridium butyricum BHD05 capable of preventing and treating colorectal cancer, and the preservation number of the clostridium butyricum BHD05 is CGMCC No. 32029; the invention further provides a clostridium butyricum genetically engineered bacterium BHC008-1, the preservation number of the clostridium butyricum genetically engineered bacterium BHC008-1 is CGMCC No.31490, the engineered bacterium can realize lactose-induced secretory expression of the human vascular endothelial growth inhibition factor VEGI192 under the anaerobic condition at the temperature of 36 DEG C in the colorectal intestinal tract of an organism, and the effects of resisting colorectal cancer and regulating colorectal micro-ecology of the clostridium butyricum are exerted at the same time. The clostridium butyricum engineering bacterium BHC008-1 is applied to colorectal cancer Balb / c mice, treatment is obvious, and a foundation is laid for application of the clostridium butyricum engineering bacterium BHC008-1 to colorectal cancer treatment.

A stent or other prosthesis may be formed by coating a single continuous wire scaffold with a polymer coating. The polymer coating may consist of layers of electrospun polytetrafluoroethylene (PTFE). Electrospun PTFE of certain porosities may permit endothelial cell growth within the prosthesis.

A stent or other prosthesis may be formed by coating a single continuous wire scaffold with a polymer coating. The polymer coating may consist of layers of electrospun polytetrafluoroethylene (PTFE). Electrospun PTFE of certain porosities may permit endothelial cell growth within the prosthesis.